EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Aspira Womens Health's enterprise value is $40.00 Mil.
Aspira Womens Health's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $9.15 Mil. Therefore, Aspira Womens Health's EV-to-Revenue for today is 4.37.
The historical rank and industry rank for Aspira Womens Health's EV-to-Revenue or its related term are showing as below:
AWH'
s EV-to-Revenue Range Over the Past 10 Years
Min: 2.09 Med: 20.85 Max: 202.15
Current: 4.37
During the past 13 years, the highest EV-to-Revenue of Aspira Womens Health was 202.15. The lowest was 2.09. And the median was 20.85.
AWH's EV-to-Revenue is ranked worse than 61.33% of 225
companies
in the Medical Diagnostics & Research industry
Industry Median: 3.13
vs AWH: 4.37
Aspira Womens Health EV-to-Revenue Historical Data
The historical data trend for Aspira Womens Health's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Aspira Womens Health's EV-to-Revenue
For the Diagnostics & Research subindustry, Aspira Womens Health's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aspira Womens Health's EV-to-Revenue Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Aspira Womens Health's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Aspira Womens Health's EV-to-Revenue falls into.
Aspira Womens Health's current Enterprise Value is $40.00 Mil.
Aspira Womens Health's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $9.15 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aspira Womens Health (NAS:AWH) EV-to-Revenue Explanation
Aspira Womens Health's share price for today is $3.0836.
Aspira Womens Health's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.01.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aspira Womens Health EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Aspira Womens Health's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Aspira Womens Health (Aspira Womens Health) Business Description
Aspira Womens Health Inc is engaged in developing and commercializing diagnostic tests for gynecologic diseases. The Company markets and sells, 1) Ova1, a blood test intended as an aid to assess the likelihood of malignancy in women with an ovarian adnexal mass for which surgery is planned when the physician's independent clinical and radiological evaluation does not indicate malignancy; (2) Overa, a second-generation biomarker reflex intended to maintain Ova1's high sensitivity while improving specificity; (3) Ova1Plus, a reflex offering which uses Ova1 as the primary test and Overa as a confirmation for Ova1 intermediate range results; and (4) OvaWatch, a lab-developed blood test intended to assist in the initial clinical assessment of malignancy risk in all women with an adnexal mass.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
AWH has been successfully added to your 